Showing papers in "Cancer Treatment Reviews in 2008"

TL;DR: Using a comprehensive literature review, the epidemiologic, economic, and health-related quality of life (HRQOL) burdens of mRCC are assessed; the estimated economic burden is large and MTTs have potential to reduce the burden and provide substantial value beyond their clinical effectiveness.

TL;DR: An overview of emerging data is provided, from basic research as well as clinical studies, highlighting the evolving role of uPA/uPAR system in tumor progression, which represents a highly attractive target that warrants further in-depth studies.

TL;DR: This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors by illustrating the development of various types of engineered nanocarriers specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies.

TL;DR: Laroscopic resection of carcinoma of the colon is associated with a long-term outcome that is similar to that after open colectomy, and laparoscopic surgery for cancer of the upper rectum is feasible.

TL;DR: The future holds more promise for the development of more effective treatment for metastatic breast cancer with new developmental agents with improved specificity for tumour cells, and those with low susceptibility to common tumour-resistance mechanisms, such as ixabepilone.

TL;DR: Existing preclinical and preliminary clinical data strongly suggest that VPA could be a drug that eventually will be used in combination therapies, either with classical cytotoxics, other molecular-targeted drugs or radiation in a number of solid tumors.

TL;DR: The current knowledge regarding the molecular pathways that underlie these apoptotic and non-apoptotic death pathways are summarized, and the clinical data that have now accumulated are discussed to evaluate their roles in tumor development and cancer treatment.

TL;DR: The pathogenesis, incidence, risk factors, diagnosis, characteristics and management of OXLIPN are reviewed and the areas of future research are highlighted.

TL;DR: Randomised clinical trials in postmenopausal women indicate that bisphosphonates prevent the bone loss and accelerated bone turnover associated with aromatase inhibitor therapy and are a promising strategy for the prevention and treatment of osteoporosis in this setting.

TL;DR: The potential synergistic anti-tumour effects of the sequential treatment of neoadjuvant chemotherapy followed by zoledronic acid in a randomised phase II study evaluating biological endpoints including apoptosis, proliferation and angiogenesis in patients with breast cancer is explored.

TL;DR: MOGCTs are rare neoplasms that affect girls and young women and have excellent prognosis at all stages of disease with optimal therapy and the majority of MOG CTs patients retain their reproductive function.

TL;DR: Chemotherapy should be considered for patients with advanced, recurrent or metastatic disease and the BEP (bleomycin, etoposide, cisplatin) is the currently preferable regimen, although overall response rate (RR) is high, the impact on disease-free or overall survival is unknown.

TL;DR: Significantly lower recurrence rates were recorded in patients subjected to MMS compared with those treated with WLE, while MMS was most effective in treating head and neck tumors.

TL;DR: This study aims to provide a comprehensive overview of the development of Aurora kinases as molecular targets for anticancer therapy by focusing on their physiological role in mitosis, their implication in oncogenesis and the potential ways of inhibiting their activity.

TL;DR: According to the available experience it seems that non-obstetrical surgery may be performed during pregnancy without an increased risk for adverse outcomes, and pregnancy has no effect on maternal prognosis when compared to non-pregnant patients matched by age, cancer stage and treatment.

TL;DR: The recent development in radiolabeled small peptides is presented, with major emphasis on somatostatin and bombesin analogs.

TL;DR: This review provides evidence for a powerful protecting role of oxygen deprivation against oxidative stress injury, androgen deprivation, chemotherapeutic and radiation cytotoxicity and proposes hypoxia as a potent tumour-induced shield against destruction.

TL;DR: Clinical relevant mechanisms which contribute to glioma resistance towards current alkylating agent-based chemotherapy are addressed, and related mechanisms and treatment strategies in the light of the cancer stem cell hypothesis are discussed.

TL;DR: A sequential approach to disease management is recommended, involving modifying the patient's lifestyle in addition to taking a stratified approach to pharmacological intervention with analgesia and anti-inflammatory medication, to encourage patient-physician communication and treatment compliance.

TL;DR: This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RankL.

TL;DR: Propose an adaptive nutritional support at each step of a multimodal GI oncological treatment is essential and should be used in daily practice but should also be included in all clinical research protocols.

TL;DR: Future trials are necessary, not only to compare combinations of existing agents, but to incorporate biological agents to chemotherapy in order to improve the treatment results of advanced, persistent or recurrent cervix cancer.

TL;DR: There is substantial evidence of a coordinate regulation of the expression of phase II enzymes and MRPs, most likely mediated by the nuclear factor-erythroid 2 p45-related factor (Nrf2) and antioxidant response elements, which will be an aid in the improvement of the chemotherapeutic treatment of cancer patients.

TL;DR: Biochemical markers of bone metabolism may allow physicians to identify which patients with metastatic bone disease are at high risk for skeletal-related events or death and who may be responding to therapy.

TL;DR: Preclinical data suggesting that bisphosphonates have antitumor potential are promising and have provided the impetus for several ongoing clinical studies, and in vivo data suggest that optimizing the dosing schedule may significantly increase survival.

TL;DR: The prospects for improving the systemic therapy of uveal melanoma using molecularly targeted agents that are currently in clinical use as well as agents being tested in clinical trials are focused on.

TL;DR: Evidence is reviewed which support the role of KiSS-1/GPR54 system in cancer biology as well as in the regulation of the reproductive function and trophoblast invasion.

TL;DR: Encouraging early clinical results supported the initiation of larger randomized trials that are currently ongoing on prevention of bone metastases by the early-generation bisphosphonate clodronate have yielded promising results in patients with breast cancer.

TL;DR: Combined toxicity analysis reveals that most patients experiencing grade 3-4 diarrhea and/or neutropenia are not homozygous for UGT1A1 *28, and future studies should combine pharmacogenetics with clinical determinants such as performance status and co-medication as to predict irinotecan toxicity and to develop predefined dosing algorithms.

TL;DR: Stereotactic body radiation therapy is associated with minimal morbidity and provides comparable local control and survival in patients with multiple co-morbidities factors and may become standard of care for operable early stages non-small cell lung cancer.